Zimmer Biomet (ZBH) announced the U.S. FDA has granted Breakthrough Device Designation for the company’s first-to-world iodine-treated total hip replacement system. This is the first product in Zimmer Biomet history to receive this designation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet’s Knee System Study: A Potential Game-Changer in Orthopedics
- Zimmer Biomet’s Knee Implant Study: A Market Game-Changer?
- Zimmer Biomet’s Persona Revision Knee System Study: A Market Game-Changer?
- Zimmer Biomet’s Latest Clinical Study: A Potential Game-Changer in Hip Arthroplasty
- Zimmer Biomet’s JuggerStitch Study: A Closer Look at Meniscal Repair Innovation